Addus HomeCare (NASDAQ:ADUS) EVP Sells $41,722.56 in Stock

Addus HomeCare Corporation (NASDAQ:ADUS) EVP Darby Anderson sold 396 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $105.36, for a total value of $41,722.56. Following the transaction, the executive vice president owned 46,246 shares in the company, valued at $4,872,478.56. This trade represents a 0.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Darby Anderson also recently made the following trade(s):

• On Tuesday, February 24th, Darby Anderson sold 733 shares of Addus HomeCare stock. The stock was sold at an average price of $106.98, for a total transaction of $78,416.34.

Addus HomeCare Stock Down 3.3%

Shares of NASDAQ ADUS traded down $3.58 on Thursday, reaching $104.02. 269,378 shares of the company’s stock traded hands, compared to its average volume of 239,147. The business’s 50 day simple moving average is $109.57 and its two-hundred day simple moving average is $113.08. Addus HomeCare Corporation has a 12 month low of $88.96 and a 12 month high of $124.43. The company has a market cap of $1.92 billion, a price-to-earnings ratio of 19.97, a price-to-earnings-growth ratio of 1.26 and a beta of 0.91. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.11.

Addus HomeCare News Roundup

Here are the key news stories impacting Addus HomeCare this week:

• Positive Sentiment: Q4 earnings/earnings call emphasized continued revenue growth, margin-leverage opportunities and an M&A-driven growth strategy for 2026 — supports longer‑term earnings upside. Addus HomeCare Earnings Call Highlights Growth And Scale
• Positive Sentiment: Stephens trimmed its price target from $140 to $135 but kept an “overweight” rating — the new target implies meaningful upside from current levels, indicating analyst confidence in the company’s outlook despite the cut. Stephens price target note
• Neutral Sentiment: Addus will participate in the Raymond James Institutional Investors Conference (investor visibility event; typically neutral but can aid liquidity/coverage). Conference participation
• Neutral Sentiment: Some published short‑interest data in the feed shows zero shares (data glitch/inconsistent reporting across sources) — treat those specific zero figures with caution. MarketBeat ADUS page
• Negative Sentiment: Significant insider selling over Feb. 24–25: CEO R. Dirk Allison sold two blocks (4,988 and 2,364 shares) and multiple senior EVPs sold smaller blocks across the two days — coordinated insider sales can pressure sentiment even if individual sales are routine and pre‑planned. See CEO filing. CEO insider-sale SEC filing
• Negative Sentiment: Short interest rose earlier in February (as of Feb. 13 there were ~1.15M shares short, ~6.5% of shares outstanding and ~4.6 days‑to‑cover) — elevated short activity can amplify downward price moves. Short interest data

Institutional Investors Weigh In On Addus HomeCare

Hedge funds have recently modified their holdings of the business. Invesco Ltd. increased its stake in shares of Addus HomeCare by 7.1% in the 4th quarter. Invesco Ltd. now owns 416,857 shares of the company’s stock worth $44,766,000 after purchasing an additional 27,683 shares in the last quarter. Caitlin John LLC bought a new stake in Addus HomeCare during the fourth quarter valued at about $183,000. Empowered Funds LLC grew its holdings in Addus HomeCare by 186.1% during the fourth quarter. Empowered Funds LLC now owns 70,927 shares of the company’s stock valued at $7,617,000 after purchasing an additional 46,137 shares during the period. XTX Topco Ltd purchased a new stake in Addus HomeCare in the fourth quarter worth about $432,000. Finally, VARCOV Co. bought a new position in shares of Addus HomeCare in the fourth quarter worth about $382,000. Institutional investors own 95.35% of the company’s stock.

Analyst Ratings Changes

ADUS has been the topic of a number of research analyst reports. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $139.00 price target on shares of Addus HomeCare in a report on Wednesday. Truist Financial set a $135.00 target price on Addus HomeCare and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Barclays lowered their target price on shares of Addus HomeCare from $117.00 to $112.00 and set an “underweight” rating on the stock in a research note on Tuesday. Stephens reduced their price target on shares of Addus HomeCare from $140.00 to $135.00 and set an “overweight” rating for the company in a research note on Wednesday. Finally, TD Cowen reissued a “buy” rating on shares of Addus HomeCare in a report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $134.33.

About Addus HomeCare

Addus HomeCare (NASDAQ: ADUS) is a leading provider of home and community-based care services for elderly, disabled, and medically complex individuals across the United States. Through a network of company-owned and franchise locations, the company delivers a broad spectrum of non-medical personal care and licensed home health services designed to support clients’ independence and quality of life.

The company’s core offerings include personal care assistance—covering daily living activities, medication reminders, and light housekeeping—and skilled home health services delivered under the supervision of registered nurses and licensed therapists.